Tammen, Harald
Kömhoff, Martin
Delić, Denis
Lund, Søren S.
Hocher, Berthold
Frankenreiter, Sandra
Hess, Rüdiger
von Eynatten, Maximilian
Mark, Michael
Klein, Thomas
Funding for this research was provided by:
Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance
Article History
Received: 27 May 2022
Accepted: 5 January 2023
First Online: 12 January 2023
Competing interests
: HT and RH are employees of PXBioVisioN, which is a contractor for Boehringer Ingelheim. MK has no conflicts of interest. SL is an employee of Boehringer Ingelheim and owns shares in Novo Nordisk and shares in dynamically traded investment funds, which might own stocks from pharmaceutical companies. DD, SF, MM and TK are employees of Boehringer Ingelheim. BH has no conflicts of interest. MvE was an employee of Boehringer Ingelheim at the time of this analysis and is currently an employee at Nestlé Health Science, Lausanne, Switzerland.